Inactive Instrument

Other languages Point Capital Inc Other OTC

Equities

US73052R1041

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment	Apr. 23
Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University	Apr. 10
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	Apr. 03
Silo Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
Silo Pharma, Inc. Exercises Option for Exclusive License Agreement for First-In-Class PTSD and Stress-Induced Anxiety Therapeutic	Mar. 20
Silo Pharma, Inc. Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain	Mar. 18
Silo Pharma?s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery	Feb. 14
Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology	Feb. 01
Silo Pharma Announces Positive Results in Alzheimer?s Disease Study	Jan. 24
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	Jan. 08
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD	Jan. 04
Silo Pharma, Partner Receive Regulatory Approval to Develop Ketamine Implant for Fibromyalgia Treatment	Dec. 28
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia	Dec. 28
Top Premarket Decliners	Nov. 20
Top Premarket Decliners	Nov. 17
Silo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Silo Pharma, Inc. to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD	Nov. 08
Silo Pharma?s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis	23-10-16
Silo Pharma, Inc. Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug Application with FDA	23-09-20
Silo Pharma, Inc. Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD	23-09-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Point Capital Inc Other OTC

Equities

US73052R1041

Other languages

Filters